Koordination und Qualität im Gesundheitswesen

OECD (1999-2004): OECD Health-Data 1999-2004, Paris.
OECD (2003): Pharmaceutical use and expenditure for cardiovascular disease and stroke: a
study of 12 OECD countries, OECD Health Working Papers No. 1, Paris
vom Orde, A., Schott, T. und Iseringhausen (2002): Behandlungsergebnisse der kardiologischen
Rehabilitation und Kosten-Wirksamkeits-Relationen – Ein Vergleich stationärer und ambulanter
Versorgungsformen. Rehabilitation, Heft 41, S. 130-139.
Ortmann, O. und König, K. (2005): Hormontherapie im Klimakterium und in der Postmenopause.
Deutsches Ärzteblatt, Heft 3, S. A144-147.
Pavcnik, N. (2002): Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
RAND Journal of Economics, Vol. 33, No. 3, S. 469-487.
Payer, L. (1992): Disease Mongers – How doctors, drug companies, and insurers are making
you feel sick, New York.
Payer, L. (1993): Andere Länder, andere Leiden. Frankfurt.
Perleth, M. und Busse, R. (2004): Health Technology Assessment (HTA) – Teil und Methode
der Versorgungsforschung. Gesundheitsökonomie und Qualitätsmanagement, Vol. 9, S. 172-
1176.
Peterson, E.D., Cowper, P.A., Jollis, J.G., Bebchuk, J.D., DeLong, E.R., Muhlbaier, L.H., Mark,
D.B. and Pryor, D.B. (1995): Outcomes of coronary artery bypass graft surgery in 24,461 patients
aged 80 years or older. Circulation, Vol. 92, S. 1185-1191.
Pfister, R., Scholz, M., Wielckens, K., Erdmann, E. and Schneider, C.A. (2004): Use of NTproBNP
in routine testing and comparison to BNP. European Journal of Heart Failure,
Vol. 15, S. 289-93.
Pharma-Brief (2001): Der 500 Millionen Bluff. Was kostet Forschung wirklich?. Pharma-Brief
Nr. 8-9, S. 1-2.
Pharmaceutical Executive (2004): Special Report Pharm Exec 50; www.pharmexec.com/
pharmexec/data/articlestandard/pharmexec/202004/95192/article.pdf (18.04.2005)
Philipps, C.O., Wright, S.M., Kern, D.E., Singa, R.M., Shepperd, S. and Rubin, H.R. (2004):
Comprehensive discharge planning with postdischarge support for older patients with
congestive heart failure: a meta-analysis. Journal of the American Medical Association,
Vol. 291, S. 1358-1367.
PhRMA (Pharmaceutical Research and Manufacturers of America) (2001): Pharmaceutical Industry
Profile 2001, Washington.
PhRMA (Pharmaceutical Research and Manufacturers of America) (2004): Pharmaceutical Industry
Profile 2004, Washington.
Pittrow, D., Kirch, W., Bramlage, P., Lehnert, H., Höfler, M., Unger, T., Sharma, A. M., and
Wittchen, H.-U. (2004): Patterns of antihypertensive drug utilization in primary care. European
Journal of Clinical Pharmacology, Vol. 60, S. 135-142.
Prosser, H. and Walley, T. (2003): Understanding why GPs see pharmaceutical representatives:
a qualitative interview study. British Journal of General Practice, Vol. 53, S. 305-311.
Prosser, H., Almond, S. and Walley, T. (2003): Influences on GP´s decision to prescribe new
drugs – the importance of who says what. Family Practice, Vol. 20, S. 61-68.
Public Citizen Group (o. J.): Would lower prescription drug prices curb drug company Research
& Development? www.citizen.org/print_article.cfm?ID=7909 (18.04.2005)
753